Evidence map›Paper›PMID 35191993›Full record

ReviewPathologie (Heidelberg, Germany)2022

[Revised German guidelines on the diagnosis and treatment of carcinoma of the uterine cervix-what's new for pathologists in 2021?]

Lars-Christian Horn, Matthias W Beckmann, Markus Follmann, Martin C Koch, Monika Nothacker, Birgit Pöschel, Frederik Stübs, Dietmar Schmidt, Anne Kathrin Höhn, Kommission zur Erstellung der S3-Leitlinie Zervixkarzinom

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pathologie (Heidelberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lars-Christian HornInstitut für Pathologie, Abteilung Mamma‑, Gynäko- & Perinatalpathologie, Universitätsklinikum Leipzig AöR, Liebigstraße 26, 04103, Leipzig, Deutschland. hornl@medizin.uni-leipzig.de.
Matthias W BeckmannUniversitätsfrauenklinik, Universitätsklinikum Erlangen, Erlangen, Deutschland.
Markus FollmannDeutsche Krebsgesellschaft, Berlin, Deutschland.
Martin C KochKlinik für Gynäkologie und Geburtshilfe, ANregiomed, Ansbach, Deutschland.
Monika NothackerAWMF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften), Berlin, Deutschland.
Birgit PöschelInstitut für Pathologie, Cölpin, Deutschland.
Frederik StübsUniversitätsfrauenklinik, Universitätsklinikum Erlangen, Erlangen, Deutschland.
Dietmar SchmidtInstitut für Pathologie, Viersen, Deutschland.
Anne Kathrin HöhnInstitut für Pathologie, Abteilung Mamma‑, Gynäko- & Perinatalpathologie, Universitätsklinikum Leipzig AöR, Liebigstraße 26, 04103, Leipzig, Deutschland.
Kommission zur Erstellung der S3-Leitlinie Zervixkarzinom

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2021, the 2015 German consensus guideline for the diagnosis and treatment of uterine cervical carcinoma was updated. The present article summarises the new recommendations for pathologists: the incorporation of the International Endocervical Adenocarcinoma Classification (IECC), which morphologically separates HPV-associated and non-HPV-associated adenocarcinomas, as well as the reporting of the prognostic relevant growth pattern of the adenocarcinoma of the endocervical subtype (Silva pattern). Histologically, multifocality has been defined as the presence of clearly invasive foci with a minimum distance between each focus of 0.2 cm. Because of its intratumoural heterogeneity, all carcinomas ≤ 2 cm in their largest dimension should be processed completely, and tumours > 2 cm should be processed with one block per centimetre of their greatest dimension. In cases of (radical) trachelectomy/hysterectomy, the distal vaginal resection margin and all parametrial tissue should be processed completely. Sentinel lymph nodes have to be processed completely by lamellation along its long axis in 0.2 cm intervals. Immunohistochemical ultrastaging is mandatory. Staging should be performed using the 2009 FIGO classification and 2017 TNM classification. Reporting the revised 2018 FIGO classification is optional. To date, molecular markers have not been relevant for prognostication and treatment decision making.

Indexed as

AdenocarcinomaCarcinomaPapillomavirus InfectionsUterine Cervical NeoplasmsFemaleHumansPathologistsCuttingDiagnosticWorkup

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.